PMID- 27431072
OWN - NLM
STAT- MEDLINE
DCOM- 20170110
LR  - 20210617
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 37
IP  - 6
DP  - 2016 Jun 14
TI  - [Valproic acid activates autophagy in multiple myeloma cell lines RPMI8226 and 
      U266].
PG  - 478-83
LID - 10.3760/cma.j.issn.0253-2727.2016.06.008 [doi]
AB  - OBJECTIVE: To investigate the effects of valproic acid (VPA) on autophagy in 
      multiple myeloma (MM) cell lines RPMI8226 and U266. METHODS: The method of dye 
      acridine orange (AO) was used for observing morphological changes of autophagy 
      under fluorescence microscope; The cell proliferation inhibition was measured by 
      MTT assay; Cells apoptosis was evaluated by flow cytometry; Autophagy-related 
      factors LC3, Beclin1 expressions changes were detected by real-time quantitative 
      PCR (Real-time PCR) and western blot assay. RESULTS: AO stainings as dispersively 
      brownish red vesicles were observed both in the control and chloroquine groups, 
      while a lot of brownish red acidic vesicles in clusters were seen in rapamycin 
      and VPA groups. The growths of RPMI8226 and U266 cells were suppressed by VPA 
      treatment in a dose-and time-dependent manner, after treatment with VPA for 24 h, 
      the IC50 were (12.03 +/- 0.23) mmol/L for RPMI8226 cells and (10.16 +/- 0.37) mmol/L 
      for U266 cells respectively; Poptotie cells of RPMI8226 and U266 increased in a 
      time-dependent manner after exposure to VPA. Real-time PCR and Western blot 
      results of RPMI8226 and U266 cells showed that gradually increased LC3, Beclin1 
      mRNA and protein expressions with LC3 Ⅰ to LC3 Ⅱ conversion rate after increasing 
      the concentration of VPA and prolonging duration of action of VPA. CONCLUSIONS: 
      The results reveal disclosed the basal level of autophagy in MM cells, VPA as a 
      autophagy activator may be one of its actions on the treatment of MM.
FAU - Zhang, Y Y
AU  - Zhang YY
AD  - Department of Hematology, Chengde Medical University Affiliated Hospital, Chengde 
      067000, China.
FAU - Zhang, Z H
AU  - Zhang ZH
FAU - Zhao, R J
AU  - Zhao RJ
FAU - Li, H
AU  - Li H
FAU - Wang, T R
AU  - Wang TR
FAU - Yan, L N
AU  - Yan LN
FAU - Gu, C H
AU  - Gu CH
FAU - Zhao, L
AU  - Zhao L
FAU - Hao, C L
AU  - Hao CL
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (BECN1 protein, human)
RN  - 0 (Beclin-1)
RN  - 0 (MAP1LC3A protein, human)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (RNA, Messenger)
RN  - 614OI1Z5WI (Valproic Acid)
SB  - IM
MH  - Apoptosis
MH  - *Autophagy
MH  - Beclin-1/metabolism
MH  - Cell Line, Tumor/drug effects
MH  - Cell Proliferation
MH  - Humans
MH  - Microtubule-Associated Proteins/metabolism
MH  - Multiple Myeloma/*pathology
MH  - RNA, Messenger/metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - Valproic Acid/*pharmacology
PMC - PMC7348343
EDAT- 2016/07/20 06:00
MHDA- 2017/01/11 06:00
PMCR- 2016/06/01
CRDT- 2016/07/20 06:00
PHST- 2016/07/20 06:00 [entrez]
PHST- 2016/07/20 06:00 [pubmed]
PHST- 2017/01/11 06:00 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - cjh-37-06-478 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2016.06.008 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):478-83. doi: 
      10.3760/cma.j.issn.0253-2727.2016.06.008.